feasibl studi indic vanadi nipt offer
compet sub segment market expect higher
traction nation system outsid us rais
revenu forecast vanadi sale
vanadi data look competit exist sequencing-bas nipt technolog
paper natur week see imag singl dna molecul high
precis nipt research report result use vanadi nipt assay
acquir vanadi earli product yet commerci vanadi abl
detect marker down syndrom sensit
fals posit fetal dna fraction statist competit
panorama assay detect rate fals posit rate
said although vanadi demonstr high sensit level
note experi sampl size small sampl
pregnanc includ analysi ii data preliminari
involv manual handl reagent may releas addit
data submit vanadi ce mark includ higher-qu data
follow autom data note target allow
comprehens data set detect rate found lower
final result uncertain overal think vanadi data
competit enough well non-high-risk pregnanc case reimburs
set nation health care system expect addit data
exhibit vanadi data look competit compar panorama offer
imag singl dna molecul high precis nipt fredrik dahl et al morgan stanley research
rais estim higher price penetr rate vanadi drive
sale growth wrote organ growth acceler
vanadi model like deploy average-risk pregnanc market
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
nation health care system estim pregnanc
test europ believ compani assay target
high-risk pregnanc like well entrench may competit
low-cost technology/test horizon key risk view vanadi
assumpt follow us vanadi penetr limit
patient get reimburs nipt sequenc provid
comprehens data beyond trisomi demonstr larger
clinic trial model us averag risk penetr ii europ
model ramp saw us high-risk offer
forecast eu averag risk penetr prior iii china
model test market base data estim
vanadi take share market forecast china
averag risk penetr prior iv row model row vanadi
sale equal europ sale consist data healthcar
spend per capita analysi impli vanadi could contribut
revenu assum nipt market worth
conserv assum share market believ nation
healthcar system find vanadi assay compel given econom
could see upsid estim penetr prove stronger
exhibit vanadi region
dilig call suggest vanadi success emerg market
euroimmun busi china may hard
compet bgi offer sequenc nipt competit price
import player china key local relationship germani alreadi
high-end well reimburs nipt offer spain robust privat
insur program cheaper offer like vanadi may struggl gain
traction/not succeed uk cover nh control
cost would welcom cheaper test like vanadi vanadi
success india altern limit
right price vanadi believ vanadi would price
substanti lower medicar price nipt well lower
offer nipt estim asp europ
row model price develop market us europ
china/row similar serum screen price consist
price target base base case revenu nip busi
multipli composit revenu multipl base growth outlook
across differ end market multipl rang ad increment
impli equiti valu associ liquid biopsi program yield
revenu multipl valuat in-lin compar diagnost compani
consid differenti technolog util consid
commerci uncertainti around diagnost solut
risk price target includ slower transit panorama
averag low risk market steeper price declin panorama forecast
slower anticip roll-out cloud-bas distribut model constel
present clinic trial data support liquid biopsi test
price target perkin base yield estim
impli ep multipl outlook incorpor organ growth
ebit margin expans valu driver includ substanti cost
ration opportun rel peer higher leverag structur
attract space diagnost risk price target includ new product launch
fail gain traction weaker industri demand fx headwind greater
anticip oper leverag less expect
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report steve
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
februari benefici own class common equiti secur follow compani cover morgan
within last month receiv compens invest bank servic thermo fisher scientif inc
next month expect receiv intend seek compens invest bank servic inc
within last month receiv compens product servic invest bank servic agil
within last month provid provid invest bank servic invest bank client relationship
follow compani inc bruker corp illumina inc mettler-toledo intern inc inc nanostr
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani inc illumina inc myriad
 co llc make market secur inc bruker corp illumina inc mettler-toledo intern
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
